{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:10:38Z","timestamp":1792789838039,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.thromres.2023.05.020","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T20:27:03Z","timestamp":1685392023000},"page":"21-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes"],"prefix":"10.1016","volume":"228","author":[{"given":"S.F.B.","family":"van der Horst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.L.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"den Exter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.E.","family":"van Mens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2023.05.020_bb0005","unstructured":"EMA Summary of Product Characteristics - Praxbind, INN-Idarucizumab. cited 2022 December 05; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/praxbind-epar-product-information_en.pdf."},{"key":"10.1016\/j.thromres.2023.05.020_bb0010","unstructured":"FDA Product Information - PRAXBIND (idarucizumab). cited 2022 December 05; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/761025lbl.pdf."},{"issue":"5","key":"10.1016\/j.thromres.2023.05.020_bb0015","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2023.05.020_bb0020","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.thromres.2023.05.020_bb0025","unstructured":"Joanna Briggs Institute (JBI) Critical Appraisal Tool - Checklist for Case Series. cited 2022 December 01; Available from: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"10.1016\/j.thromres.2023.05.020_bb0030","unstructured":"NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. cited 2022 December 01; Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"10.1016\/j.thromres.2023.05.020_bb0035","doi-asserted-by":"crossref","unstructured":"Freeman, M.F. and J.W. Tukey, Transformations related to the angular and the square root. Ann. Math. Stat., 1950. 21(4): p. 607\u2013611, 5.","DOI":"10.1214\/aoms\/1177729756"},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0040","first-page":"138","article-title":"The inverse of the Freeman \u2013 Tukey double arcsine transformation","volume":"32","author":"Miller","year":"1978","journal-title":"Am. Stat."},{"issue":"2","key":"10.1016\/j.thromres.2023.05.020_bb0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3102\/10769986010002075","article-title":"Empirical Bayes Meta-analysis","volume":"10","author":"Raudenbush","year":"1985","journal-title":"J. Educ. Stat."},{"issue":"5","key":"10.1016\/j.thromres.2023.05.020_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12535","article-title":"Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals","volume":"5","author":"Abdulrehman","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0055","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/rth2.12336","article-title":"Emergencies on direct oral anticoagulants: management, outcomes, and laboratory effects of prothrombin complex concentrate","volume":"4","author":"Bavalia","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"1","key":"10.1016\/j.thromres.2023.05.020_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/imj.13995","article-title":"Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran","volume":"49","author":"Brennan","year":"2019","journal-title":"Intern. Med. J."},{"issue":"12","key":"10.1016\/j.thromres.2023.05.020_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13748","article-title":"Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain","volume":"33","author":"Crespo-Leiro","year":"2019","journal-title":"Clin. Transpl."},{"issue":"2","key":"10.1016\/j.thromres.2023.05.020_bb0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjsurg.2020.12.034","article-title":"The AAST prospective observational multicenter study of the initial experience with reversal of direct oral anticoagulants in trauma patients","volume":"222","author":"Emigh","year":"2021","journal-title":"Am. J. Surg."},{"issue":"1","key":"10.1016\/j.thromres.2023.05.020_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0039-1695771","article-title":"Global use of Idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program","volume":"120","author":"Fanikos","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2023.05.020_bb0080","first-page":"233","article-title":"Idarucizumab reversal of dabigatran in patients with acute ischemic stroke and intracranial hemorrhage: comparison with non-idarucizumab-treated patients","volume":"35","author":"Frol","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.thromres.2023.05.020_bb0085","article-title":"Dabigatran level before reversal can predict hemostatic effectiveness of Idarucizumab in a real-world setting","volume":"7","author":"Gendron","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.thromres.2023.05.020_bb0090","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1053\/j.jvca.2021.02.029","article-title":"Appropriate use of Idarucizumab for dabigatran reversal according to the international society on thrombosis and hemostasis and French working group on perioperative hemostasis: a French retrospective study","volume":"35","author":"Gendron","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"11","key":"10.1016\/j.thromres.2023.05.020_bb0095","first-page":"699","article-title":"The use of Idarucizumab for dabigatran reversal in clinical practice: a case series","volume":"42","author":"Goriacko","year":"2017","journal-title":"P t"},{"key":"10.1016\/j.thromres.2023.05.020_bb0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.thromres.2020.11.010","article-title":"Real-world experience with reversal of dabigatran by idarucizumab","volume":"197","author":"Haastrup","year":"2021","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0105","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2020-0186","article-title":"Idarucizumab (Praxbind(\u00ae)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients","volume":"7","author":"Kalmanovich","year":"2021","journal-title":"Future Sci OA"},{"issue":"6","key":"10.1016\/j.thromres.2023.05.020_bb0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1747493019895654","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-updated series of 120 cases","volume":"15","author":"Kermer","year":"2020","journal-title":"Int. J. Stroke"},{"issue":"11","key":"10.1016\/j.thromres.2023.05.020_bb0115","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s00415-019-09492-w","article-title":"Idarucizumab administration in emergency situations: the Munich registry of reversal of Pradaxa\u00ae in clinical routine (MR REPAIR)","volume":"266","author":"K\u00fcpper","year":"2019","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.thromres.2023.05.020_bb0120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00068-019-01233-y","article-title":"Idarucizumab in major trauma patients: a single centre real life experience","volume":"47","author":"Oberladst\u00e4tter","year":"2021","journal-title":"Eur. J. Trauma Emerg. Surg."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11239-019-01835-8","article-title":"Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation","volume":"47","author":"Okishige","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s11239-018-1723-1","article-title":"Assessment of patients post reversal with idarucizumab","volume":"46","author":"Raco","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"issue":"1","key":"10.1016\/j.thromres.2023.05.020_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40256-018-0300-5","article-title":"Idarucizumab for reversal of dabigatran: single-center real-world experience","volume":"19","author":"Sheikh-Taha","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"2","key":"10.1016\/j.thromres.2023.05.020_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40256-019-00360-6","article-title":"Real world outcomes associated with Idarucizumab: population-based retrospective cohort study","volume":"20","author":"Singh","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"1499","key":"10.1016\/j.thromres.2023.05.020_bb0145","first-page":"18","article-title":"Three-month use of idarucizumab at Christchurch hospital through the emergency department and MedChartTM","volume":"132","author":"Sowerby","year":"2019","journal-title":"N Z Med J"},{"issue":"1","key":"10.1016\/j.thromres.2023.05.020_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14740\/cr1307","article-title":"Healthcare resource utilization for Oral anticoagulant reversal therapies in non-Valvular atrial fibrillation\/venous thromboembolism patients","volume":"13","author":"Spyropoulos","year":"2022","journal-title":"Cardiology Research"},{"issue":"7","key":"10.1016\/j.thromres.2023.05.020_bb0155","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/a-1704-0630","article-title":"Retrospective analysis of the effectiveness of a reduced dose of Idarucizumab in dabigatran reversal","volume":"122","author":"Stone","year":"2022","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.05.020_bb0160","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.044","article-title":"Real-world experience with Idarucizumab to reverse anticoagulant effect in dabigatran-treated patients: report of 11 cases from Taiwan","volume":"27","author":"Tsai","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"3","key":"10.1016\/j.thromres.2023.05.020_bb0165","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/europace\/euy220","article-title":"Performance of idarucizumab as antidote of dabigatran in daily clinical practice","volume":"21","author":"van der Wall","year":"2019","journal-title":"Europace"},{"issue":"10","key":"10.1016\/j.thromres.2023.05.020_bb0170","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/EJA.0000000000001185","article-title":"Idarucizumab for dabigatran reversal in daily clinical practice: a case series","volume":"37","author":"Vene","year":"2020","journal-title":"Eur. J. Anaesthesiol."},{"issue":"3","key":"10.1016\/j.thromres.2023.05.020_bb0175","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11239-017-1476-2","article-title":"Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases","volume":"43","author":"Vosko","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"10","key":"10.1016\/j.thromres.2023.05.020_bb0180","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/imj.14459","article-title":"Idarucizumab for dabigatran reversal: the first 6 months in a tertiary Centre","volume":"49","author":"Wheeler","year":"2019","journal-title":"Intern. Med. J."},{"issue":"3","key":"10.1016\/j.thromres.2023.05.020_bb0185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jjcc.2022.04.007","article-title":"Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-dabigatran surveillance 2","volume":"80","author":"Yamashita","year":"2022","journal-title":"J. Cardiol."},{"issue":"1","key":"10.1016\/j.thromres.2023.05.020_bb0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40119-020-00165-8","article-title":"Idarucizumab for emergency reversal of anticoagulant effects of dabigatran: interim results of a Japanese post-marketing surveillance study","volume":"9","author":"Yasaka","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.thromres.2023.05.020_bb0195","unstructured":"Summary Basis of Decision - Praxbind - Health Canada. 2019 cited 2022 December 07; Available from: https:\/\/hpr-rps.hres.ca\/reg-content\/summary-basis-decision-detailTwo.php?linkID=SBD00322#Brandname4."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2023.05.020_bb0205","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0210","first-page":"391","article-title":"Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French working group on perioperative Haemostasis (GIHP) - September 2016","volume":"37","author":"Albaladejo","year":"2018","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1016\/j.thromres.2023.05.020_bb0215","unstructured":"Pharmaceutical Management Agency (Pharmac), Hospital Medicines List (HML) - Idarucizumab. cited 2022 December 07; Available from: https:\/\/schedule.pharmac.govt.nz\/2023\/02\/01\/HML.pdf."},{"key":"10.1016\/j.thromres.2023.05.020_bb0220","unstructured":"Japanese Package Insert - Idarucizumab. cited 2022 December 07; Available from: https:\/\/www.pmda.go.jp\/files\/000222407.pdf."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0225","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jth.15222","article-title":"Definition of haemostatic effectiveness in interventions used to treat major bleeding: communication from the ISTH SSC subcommittee on control of anticoagulation","volume":"19","author":"Khorsand","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2023.05.020_bb0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fca-2020-0014","article-title":"GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke","volume":"17","author":"Bassand","year":"2021","journal-title":"Futur. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2023.05.020_bb0235","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1160\/TH15-01-0063","article-title":"Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis","volume":"114","author":"Chai-Adisaksopha","year":"2015","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1016\/j.thromres.2023.05.020_bb0240","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.2019001605","article-title":"How I assess and manage the risk of bleeding in patients treated for venous thromboembolism","volume":"135","author":"Klok","year":"2020","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:50:32Z","timestamp":1758736232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823001524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":48,"alternative-id":["S0049384823001524"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.05.020","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}